$112 million ADC collaboration marks third Bristol-Myers Squibb/Ambrx deal in two years

The team-up of the two companies will focus on the discovery and development of novel antibody-drug conjugates against oncology targets, using Ambrx's protein medicinal chemistry technology
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
SAN DIEGO—On May 3, Ambrx Inc. entered into acollaboration agreement with Bristol-Myers Squibb Co. for the discovery anddevelopment of novel antibody-drug conjugates (ADCs) against cancer, usingAmbrx's protein medicinal chemistry technology. This announcement marks Ambrx'sthird deal with Bristol-Myers Squibb since 2011.
 
 
Under terms of the agreement, Ambrx will receivean upfront payment of $15 million, funding for discovery and researchactivities, and potential development, regulatory and sales-based milestonepayments of as much as $97 million per product resulting from thecollaboration. Bristol-Myers Squibb will receive worldwide rights to developand commercialize products resulting from the collaboration, while Ambrx iseligible to receive royalties on net sales.
 
 
This follows the announcement of a big ADC dealwith Japan's Astellas Pharma Inc. in April—like the most recent Bristol-MyersSquibb deal, oncology is the focus—for $15 million up front and as much as $285million in potential near- and long-term research, development, regulatory andsales-based milestones.
 
 
The two previous agreements with Bristol-MyersSquibb were separately inked, though both were finalized in September 2011. Onetargets fibroblast growth factor 21 (FGF-21)—a naturally occurring protein withreported benefits on lowering blood glucose, raising HDL cholesterol  and reducing weight—for the potentialtreatment of type 2 diabetes. The other deal centers on Relaxin, a hormone involvedwith childbirth, for the potential treatment of heart failure.
 
 
"Bristol-Myers Squibb is a globalbiopharmaceutical leader with expertise developing and commercializing novelmedicines for the treatment of cancer and other diseases, and we are pleased toenter into a third collaboration with the company to include another aspect ofour technology platform," said Dr. Lawson Macartney, CEO of Ambrx. "We lookforward to working together to further utilize Ambrx's technology to discoverand advance these antibody drug conjugates for oncology indications."
 


About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue